Reply To: Bristol Myers Squibb Acquisition of Celgene

Home Fairmark Forum Taxation of Investments Bristol Myers Squibb Acquisition of Celgene Reply To: Bristol Myers Squibb Acquisition of Celgene

#5318
kaneohe
Participant

Isn’t it capital gains………Sch D/Sch 8949?

“U.S. Federal Income Tax Consequences to U.S. Holders

The receipt of the merger consideration by U.S. holders pursuant to the merger will be a taxable transaction for U.S. federal income tax purposes. In general, for U.S. federal income tax purposes, a U.S. holder will recognize taxable capital gain or loss in an amount equal to the difference, if any, between (i) the sum of (A) the amount of cash, including cash received in lieu of fractional shares, received in the merger, (B) the fair market value of the shares of Bristol-Myers Squibb common stock received in the merger and (C) the fair market value of the CVRs received in the merger, each determined on the date of the consummation of the merger and (ii) such U.S. holder’s adjusted tax basis in its shares of Celgene common stock exchanged therefor.”